Pluristem Therapeutics Inc.
PSTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -35.5% | 14.8% | 130.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 36.4% | 35.3% | 31.9% | 60% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,019% | -569.6% | -1,309.6% | -2,811.9% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -1,940.5% | 1,834.1% | -1,483.6% | 998.4% |
| EPS | -0.65 | -1.78 | -0.94 | -0.53 |
| % Growth | 63.5% | -89.4% | -77.4% | – |
| EPS Diluted | -0.65 | -1.78 | -0.94 | -0.53 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$0 | $0 | $0 |
| Interest Expense | $0 | -$0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,826.9% | -2,145.3% | -1,309.6% | -2,811.9% |